Efficacy of AM 101 in Patients With Acute Inner Ear Tinnitus

Tinnitus Clinical Trial

Official title:

Efficacy of AM 101 in Patients With Acute Inner Ear Tinnitus: A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Multiple Dose, Group Comparison Phase II Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00860808
• Other study ID #: AM-101-CL-08-01
• Secondary ID: EudraCT number:
• Status: Completed
• Phase: Phase 2
• First received: March 11, 2009
• Last updated: February 12, 2013
• Start date: March 2009
• Est. completion date: August 2011

Study information

• Verified date: February 2013
• Source: Auris Medical, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Federal Institute for Drugs and Medical DevicesBelgium: The Federal Public Service (FPS) Health, Food Chain Safety and EnvironmentNetherlands: The Central Committee on Research Involving Human Subjects (CCMO)Poland: The Central Register of Clinical Trials
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is the evaluation of the therapeutic benefit of intratympanic AM 101 injections in comparison to placebo in the treatment of persistent acute inner ear tinnitus following acute sensorineural hearing loss.

Description:

Tinnitus may seriously impact the ability to sleep, relax, or to concentrate, or lead to tiredness, irritation, nervousness, despair, frustration, or depression, thus severely impacting the quality of life and health of the affected person. To date, there exists no pharmaceutical treatment for persisting tinnitus.

Non-clinical studies with AM-101 have shown that the inhibition of cochlear NMDA receptors is successful in suppressing tinnitus without affecting normal glutamate neurotransmission respectively hearing function. In particular, it could be demonstrated that local administration of AM-101 in a single dose resulted in a complete suppression of tinnitus induced by acute acoustic trauma without any relapse thereafter.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 248
• Est. completion date: August 2011
• Est. primary completion date: May 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Persistent tinnitus following acute acoustic trauma, sudden deafness, or acute otitis media with onset less than three months ago (i.e. acute tinnitus)

• Tinnitus provoking incident of acute acoustic trauma, sudden deafness or acute otitis media is documented by audiogram and medical report and at onset resulted in an inner ear hearing loss of at least 15 dB in two adjacent frequencies

• Minimum Masking Level (MML) of at least 5 dB SL

• Age = 18 years and = 65 years

• Negative pregnancy test for women of childbearing potential

• Willing and able to attend the on-study visits

• Must be able to read and understand the relevant study documents

• Written informed consent before participation in the study

Exclusion Criteria:

• Tinnitus that is not completely maskable

• Fluctuating tinnitus

• Intermittent tinnitus

• Meniere's Disease

• Acute or chronic otitis media or otitis externa

• Any ongoing therapy known as potentially tinnitus-inducing (e.g. aminoglycosides, cisplatin, loop diuretics, high doses of aspirin, quinine etc.)

• Any drug-based therapy for inner ear hearing loss that is ongoing or was performed in the past 2 weeks, e.g. prednisolone, dexamethasone, pentoxifylline, betahistine, diazepam, carbamazepine, sodium valproate and antidepressants

• Concomitant use of any other NMDA receptor antagonist (e.g. memantine, dextromethorphan, ifenprodil)

• Any ongoing or planned concomitant medication for the treatment of tinnitus until 90 days after study drug application

• History or presence of drug abuse or alcoholism

• Any clinically relevant respiratory, cardiovascular, neurological (except vertigo), or psychiatric disorder

• Known hypersensitivity, allergy or intolerance to the study medication or any history of severe abnormal drug reaction

• Women who are breast-feeding, pregnant or who plan a pregnancy during the trial

• Women of childbearing potential who declare being unwilling or unable to practice contraception such as hormonal contraceptives, sexual abstinence or intercourse with a vasectomised partner

• Concurrent participation in another clinical trial with an investigational drug or participation in another clinical trial with an investigational drug within 30 days prior to study entry

• Any drug-based therapy for otitis media that is ongoing or was performed in the past 2 weeks

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Tinnitus

Intervention

Drug:
• AM-101
Triple intratympanic injection (one on each day 1, 2, and 3)

Locations

Country	Name	City	State
Germany	Bundeswehrkrankenhaus Ulm	Ulm

Sponsors (1)

Lead Sponsor	Collaborator
Auris Medical AG

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in the minimum masking level from Baseline to Day 90		Day 90	No
Secondary	Standard audiological evaluations		D7, D30, D90	No
Secondary	Questionaires evaluating the impact of tinnitus		D7, D30, D90	No